Eli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s Disease Drug

Eli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s Disease Drug
Eli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently under development as a promising therapy for Alzheimer’s disease. Alzheimer’s disease is characterized by two important pathological features — amyloid-β plaques and neurofibrillary tangles — and is the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *